小分子化合物类肿瘤靶向治疗新药研究进展  

Advance of the targeted therapy against tumors with small molecule compounds

作　　者：王淑月[1] 贾湘曼[1] 张爱华[1] 姚书渊[1] 

机构地区：[1]河北医科大学药学院药物化学室,石家庄050017

出　　处：《中国新药杂志》2005年第10期1145-1148,共4页Chinese Journal of New Drugs

摘　　要：肿瘤的分子靶向治疗研究进展迅速,靶向治疗新药不断涌现。小分子化合物类靶向治疗新药Glivec,Iressa,OSI-774,CI-1033,PKI166和GW572016等可以片剂等形式口服给药,不依赖基因,不引起免疫反应。易于经结构修饰或结构改造使其更适合临床需要,成本低,便于推广,是肿瘤分子靶向治疗研究的热点。As the targeted therapy against tumors with small molecule compounds is currently dominated by the search for effective therapeutic agents, immense commercial and academic achievements have been impressively augmenting. Some of such small molecular compounds are under investigation and eventually marketed for the treatment of tumors, such as Glivec, Iressa, OSI-774, CI-1033, PKI166, GW572016 and so on. These new agents show most effective antitumor responses with less adverse immune reactions and nonmodulation of genes and their proteins. They demonstrate easy modification and transformation of chemical structures, cost saving, and flexible compliance with therapy, becoming the most attractive advantages of the small molecular compounds for the targeted therapy against tumors.

关 键 词：肿瘤 靶向治疗药物 小分子化合物 

分 类 号：R979.1[医药卫生—药品] R944.9[医药卫生—药学]